Research and Markets: Bio-Europe 2014 Cancer Drug Pipeline Update: 264 Companies Developing 1572 Cancer Drugs in 4673 Developmental Projects in Cancer

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/r3gz5f/bioeurope_2014) has announced the addition of the "Bio-Europe 2014 Cancer Drug Pipeline Update" report to their offering.

There are today 264 companies plus partners developing 1572 cancer drugs in 4673 developmental projects in cancer. In addition, there are 20 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 784 drugs. Bio-Europe 2014 Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 625 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.

To date 579 out of the 587 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 86 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators

Includes more than 264 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 1572 BIO-Europe 2014 cancer drugs in development, which have a total of 4673 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs

  • Marketed # 232
  • Registered # 1
  • Pre-registration # 16
  • Phase III # 152
  • Phase II # 447
  • Phase I # 571
  • Preclinical # 694
  • No Data # 31
  • Suspended # 20
  • Ceased # 784

For more information visit http://www.researchandmarkets.com/research/r3gz5f/bioeurope_2014

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology